A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

NCT05604885 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: AP1189, 60 mg
DRUG: AP1189, 80 mg
DRUG: AP1189, 100 mg
DRUG: Placebo

Sponsor

SynAct Pharma Aps

Collaborators

[object Object]